Lv64
2530 积分 2023-07-10 加入
Genetic architecture of the inflammatory bowel diseases across East Asian and European ancestries
2小时前
已完结
CMD-OPT model enables the discovery of a potent and selective RIPK2 inhibitor as preclinical candidate for the treatment of acute liver injury
10天前
已完结
Discovery of a novel RIPK2 inhibitor for the treatment of inflammatory bowel disease
10天前
已完结
RIPK2 inhibitors for disease therapy: Current status and perspectives
10天前
已完结
Discovery of Potent and Balanced Dual RIPK2 and 3 Inhibitors as a New Strategy for the Treatment of Inflammatory Bowel Diseases
10天前
已完结
Repurposing of clinical-stage FLT3 inhibitor HYML-122 as a potent RIPK2 inhibitor for the treatment of inflammatory bowel disease
10天前
已完结
Receptor Interacting Ser/Thr-Protein Kinase 2 as a New Therapeutic Target
10天前
已完结
A RIPK2 inhibitor delays NOD signalling events yet prevents inflammatory cytokine production
10天前
已完结
RIPK2 as a promising druggable target for autoimmune diseases
10天前
已完结
Real-Life Durability and Risk Factors for Biologic Discontinuation in Pediatric Inflammatory Bowel Disease: Results from the Sigenp IBD Registry
21天前
已完结
皖公网安备34019202002308
